BOSTON SCIENTIFIC CORP — M&A Activity 2015

Aug 4, 2015

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, DC 20549*

*FORM 8-K*

*CURRENT REPORT*

*PURSUANT TO SECTION 13 OR 15(d) OF THE*

*SECURITIES EXCHANGE ACT OF 1934*

Date of Report (Date of earliest event reported): August 3, 2015

*BOSTON SCIENTIFIC CORPORATION*

(Exact name of registrant as specified in charter)

DELAWARE	1-11083	04-2695240
(State or other	(Commission	(IRS employer
jurisdiction of	file number)	identification no.)
incorporation)

300 Boston Scientific Way, Marlborough, Massachusetts	01752-1234
(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code: (508) 683-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\108736\15-16835-1\task7522974\16835-1-ba.htm',USER='108736',CD='Aug 4 01:17 2015'

*Item 8.01 Other Events.*

On August 3, 2015, Boston Scientific Corporation (the “Company”) completed its acquisition of the American Medical Systems male urology portfolio, which includes the Men’s Health and Prostate Health businesses (the “AMS Portfolio Acquisition”), under the terms of the definitive purchase agreement, which was executed and announced on March 2, 2015.

On August 4, 2015, the Company issued a press release announcing the completion of the AMS Portfolio Acquisition. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

*Item 9.01 Financial Statements and Exhibits.*

Exhibit No.	Description
99.1	Press Release issued by Boston Scientific Corporation dated August 4, 2015

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\108736\15-16835-1\task7522974\16835-1-ba.htm',USER='108736',CD='Aug 4 01:17 2015'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

August 4, 2015
By:	/s/ Vance R. Brown
	Vance R. Brown
	Vice President and Chief Corporate Counsel

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\108736\15-16835-1\task7522974\16835-1-ba.htm',USER='108736',CD='Aug 4 01:17 2015'

*INDEX TO EXHIBITS*

Exhibit No.	Description
99.1	Press Release issued by Boston Scientific Corporation dated August 4, 2015

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\108736\15-16835-1\task7522974\16835-1-ba.htm',USER='108736',CD='Aug 4 01:17 2015'